(Q43053414)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Jean Bastin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Anthony Béhin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Fatima Djouadi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

P Laforêt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

F Aubey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Mogenet

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S Romano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

D Ricquier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S Gobin-Limballe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Vassault

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

B Eymard

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J L Bresson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

26 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

101-108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20505667%20AND%20SRC:MED&resulttype=core&format=json

Mitochondrial fatty acid oxidation defects--remaining challenges.

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Carnitine Palmitoyltransferase II Deficiency: A Clinical, Biochemical, and Molecular Review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Bezafibrate for an inborn mitochondrial beta-oxidation defect.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Characterization of fatty acid oxidation in human muscle mitochondria and myoblasts.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Regulation of muscle fiber type and running endurance by PPARdelta

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

PPARs: transcription factors controlling lipid and lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

PPAR delta: a dagger in the heart of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

A mitochondrial tRNA aspartate mutation causing isolated mitochondrial myopathy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Recognition and management of fatty acid oxidation defects: a series of 107 patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Rapid diagnosis of long chain and medium chain fatty acid oxidation disorders using lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021

Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.55

7 January 2021